semaglutide studies in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial Semaglutide 2·4 mg once a

Caregivers contributed to study procedures by administering the investigational product, completing dosing diaries, reporting adverse events, and completing caregiver-reported instruments

/ 10 Direct Meds is the only compounded provider in our catalog to ask for an actual blood-pressure RANGE and a resting heart-rate range, both with AHA-aligned categories

Prioritize protein and resistance training This does not reduce GI side effects but it directly counters the muscle loss risk, which is the most consequential long-term side effect for body composition

Semaglutide (brand names Ozempic and Wegovy) is a long-acting GLP-1 receptor agonist used for type 2 diabetes and weight management

Availability of Data and Material Not applicable Ethics Approval Not applicable Consent to Participate Not applicable Consent for Publication Not applicable Author Contributions All authors (F.P, S.M.O, J.M, F.C.S) meet ICMJE authorship criteria, made substantial contributions to the conception and design of the work and to drafting or critically revising the manuscript, approved the final version, and agree to be accountable for all aspects of the work

InsideOut Institute